Levodopa/Carbidopa/Entacapone Teva

Levodopa, carbidopa, and entacapone, the active ingredients in Levodopa/Carbidopa/Entacapone Teva, are antiparkinson agents presented as tablets for oral use. They treat Parkinson's disease by improving motor function in adult patients.

GNH USA supplies Levodopa/Carbidopa/Entacapone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is an oral antiparkinson combination that targets motor fluctuations in Parkinson's disease.

- Parkinson's disease (early stage): enhances levodopa response and improves daily motor activities. - Parkinson's disease (advanced stage): reduces OFF periods and stabilises symptom control. - Parkinson's disease (wearing‑off phenomenon): prolongs levodopa plasma half‑life, decreasing the frequency of motor fluctuations.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Cardiac arrhythmias - Neuroleptic malignant syndrome - Hepatic dysfunction (rare).

Before initiating therapy, consider the following safety measures.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; assess liver enzymes regularly. - Cardiovascular disease: observe blood pressure and heart rate for hypotensive episodes. - Psychiatric history: watch for hallucinations, confusion, or mood changes. - Concomitant MAO‑B inhibitors: avoid co‑administration due to risk of hypertensive crisis. - Pregnancy: safety unknown; prescribe only if potential benefit justifies the risk. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several medicines; categorise the risk level.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Antipsychotics (e.g., haloperidol): can diminish antiparkinson efficacy. - Anticholinergic agents: may mask motor symptom changes.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: increase risk of serotonin syndrome. - Diuretics: may exacerbate orthostatic hypotension. - Antihypertensive drugs: may potentiate blood‑pressure‑lowering effects.